CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
ACTIMMUNEdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02584608
NCT02584608Phase 2Completed
CompareCT.gov

Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 Osteopetrosis

Indiana University·interventional·Posted Oct 22, 2015·Updated Jan 8, 2021

In Brief

A Phase 2 clinical trial evaluating ACTIMMUNE for Autosomal Dominant Osteopetrosis Type 2. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This study is an open label use of ACTIMMUNE for patients with Autosomal Dominant Osteopetrosis Type 2(ADO2). Effects of treatment will be evaluated after 14 weeks on ACTIMMUNE by bone resorption markers. This study will treat 12 patients with ADO2 recruited from Indiana University and Riley Hospital for Children at Indiana University Health.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutosomal Dominant Osteopetrosis Type 2
CountriesUnited States
CollaboratorsHorizon Pharma Ireland, Ltd., Dublin Ireland

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 22, 2015
Enrollment StartJan 1, 2016
Primary CompletionNov 12, 2019
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.7 years ago

Interventions

ACTIMMUNEdrug